<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204616</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.202699</org_study_id>
    <secondary_id>2019-004294-13</secondary_id>
    <nct_id>NCT04204616</nct_id>
  </id_info>
  <brief_title>A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)</brief_title>
  <official_title>A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152)&#xD;
      in participants with prurigo nodularis (PN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) by Severity</measure>
    <time_frame>Up to 192 weeks</time_frame>
    <description>Incidence of AEs including AEs of Special Interest (AESIs), Treatment Emergent AEs (TEAEs) and Serious AEs (SAEs) by severity as mild, moderate or severe will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with relevant investigational product. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TEAE is an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Investigator Global Assessment (IGA) Success up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Percentage of participants with an IGA success (defined as IGA of 0 [Clear] or 1 [Almost clear]) up to Week 184 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Improvement of &gt;=4 from Baseline in Peak Pruritus (PP) Numeric Rating Scale (NRS) up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Percentage of participants with an improvement of &gt;= 4 from baseline in PP NRS up to Week 184 will be reported. The PP NRS has a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Low Disease Activity State up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Percentage of participants with low disease activity state (that is, IGA &lt;=2) up to Week 184 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Pruriginous Lesions with Excoriations/Crusts up (PAS item 5a) up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>PAS will include a count of the number of lesions in a representative area and a calculated staging (stage 0 to stage 4) based on the percentage of lesions with excoriations/crusts and healed lesions compared to all lesions. PAS item 5a reflects the current itch/scratch activity. It is used to estimate what percentage of the pruriginous legions show excoriations/crusts. 100 percent (%) = All pruriginous lesions have excoriations/crusts. Percentage of pruriginous lesions with excoriations/crusts (PAS item 5a) up to Week 184 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Healed Prurigo Lesions (PAS item 5b) up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>PAS item 5b item reflects the stage of the prurigo. It is used to estimate what percentage of the pruriginous lesions have healed.100% = all pruriginous lesions have healed. Percentage of healed prurigo lesions (PAS item 5b) up to Week 184 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Number of Lesions in Representative Area (PAS item 4) up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Change from baseline in number of lesions in representative area (PAS item 4) up to Week 184 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with PP NRS &lt;2 up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Percentage of participants with PP NRS &lt;2 up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in PP NRS up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Percent change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in PP NRS up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Absolute change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Average Pruritus (AP) NRS &lt;2 up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with AP NRS less than (&lt;) 2 up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Improvement of &gt;=4 from Baseline in AP NRS up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with an improvement of &gt;=4 from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in AP NRS up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percent change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in AP NRS up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Absolute change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being &quot;no itch&quot; and 10 being &quot;worst itch imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Improvement of &gt;=4 from Baseline in Sleep Disturbance (SD) NRS up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Percentage of participants with an improvement of &gt;=4 from baseline in Sleep Disturbance (SD) NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being &quot;no sleep loss related to the symptoms of my skin disease (prurigo nodularis)&quot; and 10 being &quot;I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in SD NRS up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Percent change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being &quot;no sleep loss related to the symptoms of my skin disease (prurigo nodularis)&quot; and 10 being &quot;I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in SD NRS up to Week 184</measure>
    <time_frame>Up to Week 184</time_frame>
    <description>Absolute change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being &quot;no sleep loss related to the symptoms of my skin disease (prurigo nodularis)&quot; and 10 being &quot;I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Prurigo Nodularis (PN)-associated Pain Frequency up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Change from baseline in PN-associated pain frequency up to Week 184 will be reported. The pain frequency will be assessed on a scale of 0 to 5 where 0 = never, 1 = less than once a week, 2 = 1-2 days a week, 3 = 3-4 days a week, and 4 = 5-6 days a week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PN-associated Pain Intensity up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Change from baseline in PN-associated pain intensity up to Week 184 will be reported. The pain intensity will be assessed on a scale of 0 to 10, with 0 being &quot;no pain&quot; and 10 being &quot;the worst unbearable pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting low Disease Activity Based on Patient Global Assessment of Disease (PGAD) up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants reporting low disease activity (clear, almost clear, or mild) based on Patient Global Assessment of Disease (PGAD) up to Week 52 to be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Satisfied with Study Treatment Based on Patient Global Assessment of Treatment (PGAT) up to Week 52</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants satisfied with study treatment (good, very good, or excellent) based on Patient Global Assessment of Treatment (PGAT) up to Week 52 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Change of &gt;=4 from Baseline in Dermatology Life Quality Index (DLQI) up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Percentage of participants with a change of &gt;=4 from baseline in Dermatology Life Quality Index (DLQI) up to Week 184 will be reported. The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant will rate each question ranging from 0 (not at all) to 3 (very much). A higher total score indicates a poorer quality of life (QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184</measure>
    <time_frame>Baseline up to Week 184</time_frame>
    <description>Change from baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184 will be reported. The EQ-5D instrument is a validated questionnaire, completed by the participant that consists of 2 parts. The first part consists of 5 multiple choice QoL questions and the second is a 100 point Visual Analog Scale (VAS) with 0 being &quot;Worst imaginable health state&quot; and 100 being &quot;Best imaginable health state&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Permanent Study Drug Discontinuation</measure>
    <time_frame>Baseline to 184 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rescue Therapy</measure>
    <time_frame>Baseline to 184 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Any Rescue Treatment by Rescue Treatment</measure>
    <time_frame>Baseline up to 184 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Prurigo Nodularis</condition>
  <arm_group>
    <arm_group_label>Nemolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants weighing less than (&lt;) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (&gt;=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemolizumab</intervention_name>
    <description>Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.</description>
    <arm_group_label>Nemolizumab</arm_group_label>
    <other_name>CD14152</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who may benefit from study participation in the opinion of the&#xD;
             investigator and participated in a prior nemolizumab study for PN including: (a).&#xD;
             Participants who completed the treatment period in a phase 3 pivotal study&#xD;
             (NCT04501666 or NCT04501679) and enroll within 56 days OR (b).Participants who were&#xD;
             previously randomized in the nemolizumab phase 2a PN study (NCT03181503)&#xD;
&#xD;
          -  Female participants of childbearing potential (that is, fertile, following menarche&#xD;
             and until becoming post-menopausal unless permanently sterile) must agree either to be&#xD;
             strictly abstinent throughout the study and for 12 weeks after the last study drug&#xD;
             injection, or to use an adequate and approved method of contraception throughout the&#xD;
             study and for 12 weeks after the last study drug injection&#xD;
&#xD;
          -  Participant willing and able to comply with all of the time commitments and procedural&#xD;
             requirements of the clinical study protocol, including periodic weekly recordings by&#xD;
             the participant using an electronic handheld device provided for this study&#xD;
&#xD;
          -  Understand and sign an informed consent form (ICF) before any investigational&#xD;
             procedure(s) are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who, during their participation in a prior nemolizumab study, experienced&#xD;
             an adverse event (AE) which in the opinion of the investigator could indicate that&#xD;
             continued treatment with nemolizumab may present an unreasonable risk for the&#xD;
             participant&#xD;
&#xD;
          -  Body weight &lt; 30 kg&#xD;
&#xD;
          -  Pregnant women (positive pregnancy test result at screening or baseline visit),&#xD;
             breastfeeding women, or women planning a pregnancy during the clinical study&#xD;
&#xD;
          -  Any medical or psychological condition that may put the participant at significant&#xD;
             risk according to the investigator's judgment, if he/she participates in the clinical&#xD;
             study, or may interfere with study assessments (example, poor venous access or&#xD;
             needle-phobia)&#xD;
&#xD;
          -  Planning or expected to have a major surgical procedure during the clinical study&#xD;
&#xD;
          -  Participants unwilling to refrain from using prohibited medications during the&#xD;
             clinical study&#xD;
&#xD;
          -  History of alcohol or substance abuse within 6 months prior to the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Research &amp; Development</last_name>
    <phone>817-961-5000</phone>
    <email>clinical.studies@galderma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Clinical Project Manager</last_name>
    <phone>817-961-5000</phone>
    <email>clinical.studies@galderma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>205-914-5104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>714-531-2966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>858-278-8470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>760-653-2251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>94404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>310-828-8887</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>202-741-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>954-243-5559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>561-499-0660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>561-958-3116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>727-935-0508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>305-649-7999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>305-243-4472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>305-652-8600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>386-523-0768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>954-435-3709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Galderma Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>706-322-1717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>478-742-2180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>770-252-6900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>312-335-2070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Galderma Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>512-470-7976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma I Galderma Investigational Site</name>
      <address>
        <city>Lake Bluff</city>
        <state>Illinois</state>
        <zip>60044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>212-750-2905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>317-516-5030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>785-272-6860</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>502-585-9059</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>410-955-5933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>617-636-7462</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>734-936-6674</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>269-428-5199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>816-364-1515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>314-362-2643</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>702-433-4156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>646-962-3376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Galderma Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>847-234-1177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>336-841-2040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>512-470-7976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>336-713-4116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>513-558-6607</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>216-844-8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>614-336-7880</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>215-563-7330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>608-848-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>615-410-3460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Galderma Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78738</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>512-580-4633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>469-661-2729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>512-454-3781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>713-661-4383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>512-279-2545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>713-528-1209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>801-542-8190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Galderma Investigational Site</name>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>385-327-5115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>301-984-3376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>608-848-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>304-599-5478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+43 316 3850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+43 732 76760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+43 128 8020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+32 2 764 11 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+32 9 332 22 87</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+32 2 477 60 12</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+32 1 633 79 50</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+32 4 366 80 56</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>AL</state>
        <zip>T3E OB2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>15873927546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>15194351738</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2M 4J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>'+1 416-222-7546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K OH6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>13066447546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Calgary</city>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+1 403-299-5821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Drummondville</city>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>London</city>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+1 519-204-6868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Markham</city>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+1 905-471-8182</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Toronto</city>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+1 416 633-0001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+45 7845 0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+45 38 67 38 67</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 5 5 79 56 79</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 2 98 22 33 15</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 2 40 08 33 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 4 92 03 62 23</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 1 56 01 67 02</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 1 42 49 99 61</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pierre-B√©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 4 78 86 33 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 2 32 88 89 90</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint-√âtienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 4 77 82 83 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 5 67 77 81 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+33 4 75 75 75 49</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 241 803 5655</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 821 650 7250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 592 274 3131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderme Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 304 505 18065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 228 287 15370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 615 110 74131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 351 4580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>D√ºsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 211 811 7602</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Eppendorf</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 404 280 32650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>G√∂ttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 551 396 6478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 345 557 3969</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 407 410 52630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 622 156 6243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+494315000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>L√ºbeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 431 500 21200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 613 117 2903</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>M√ºnich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 894 400 56010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>M√ºnich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 894 140 3184</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>M√ºnster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 251 835 7470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>T√ºbingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+49 707 129 84555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Kecskem√©t</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+36 76 516 700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+36 62 341 502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+36 56 999 525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 95 3781392</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 99 458 5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 10 5551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 862 3681</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 59 422 2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 81 7461111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 521 703111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 75 5851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 6 52661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 6 30151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+39 444 75-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+82 31 412 5103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+82 2920 5479</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+82 2228 2080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+82 2290 8114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+82 2829 5221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+31 50 361 6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+31 88 75 588 75</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chorz√≥w</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 666674565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Czƒôstochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Galderma Investigational Site</last_name>
      <phone>+48343904451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gda≈Ñsk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I Galderma Investigational Site</last_name>
      <phone>+48587129970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48587128018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma I Galderma Investigational Site</last_name>
      <phone>+48322021414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Krak√≥w</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 571 241 412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 81 532 50 41</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-900</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 89 532 62 21</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Pozna≈Ñ</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48616414180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Rzesz√≥w</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 17 86 66 294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 91 433 29 19</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational site</last_name>
      <phone>+48 22 400 40 41</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 603 753 493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 22 508 14 81</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>*48 22 111 50 05</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48223801074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wroc≈Çaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+487726000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wroc≈Çaw</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 22 266 04 17</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Wroc≈Çaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 503711714</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>≈Å√≥d≈∫</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 42 663 14 60</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>≈Å√≥d≈∫</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+48 42 230 96 57</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+34 932 91 90 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+34 928 45 00 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+46 8 517 700 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+41 31 632 22 18</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+41 21 314 04 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Obb√ºrgen</city>
        <zip>6363</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+41 41 612 60 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+41 71 494 11 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Weinfelden</city>
        <zip>8570</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+41 71 620 00 90</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+44 1384 456111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+44 141 211 2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+44 20 7188 7188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma Investigational Site</last_name>
      <phone>+44 191 233 6161</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

